{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:15:54Z","timestamp":1783401354878,"version":"3.54.6"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Medical and Health Science Program of Zhejiang Province","award":["2025KY1886"],"award-info":[{"award-number":["2025KY1886"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08204-w","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:22:10Z","timestamp":1780921330000},"page":"4533-4541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and safety of firsekibart versus compound betamethasone in frequent gout flares: a multicenter retrospective study"],"prefix":"10.1007","volume":"45","author":[{"given":"Mengjie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0989-7336","authenticated-orcid":false,"given":"Yongjun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"3","key":"8204_CR1","doi-asserted-by":"publisher","first-page":"ITC33","DOI":"10.7326\/ANNALS-24-03951","volume":"178","author":"JD FitzGerald","year":"2025","unstructured":"FitzGerald JD (2025) Gout. Ann Intern Med 178(3):ITC33\u2013ITC48. https:\/\/doi.org\/10.7326\/ANNALS-24-03951","journal-title":"Ann Intern Med"},{"issue":"10","key":"8204_CR2","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/art.43215","volume":"77","author":"R Poulsen","year":"2025","unstructured":"Poulsen R, Dalbeth N (2025) Gout and NLRP3 inflammasome biology. Arthritis Rheumatol 77(10):1317\u20131326. https:\/\/doi.org\/10.1002\/art.43215","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"8204_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2022.11390","volume":"328","author":"E Cipolletta","year":"2022","unstructured":"Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A (2022) Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA 328(5):440\u2013450. https:\/\/doi.org\/10.1001\/jama.2022.11390","journal-title":"JAMA"},{"issue":"4","key":"8204_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1053\/j.ajkd.2025.04.020","volume":"86","author":"RA Ostrowski","year":"2025","unstructured":"Ostrowski RA (2025) Gout Management in Patients With CKD: A Review. Am J Kidney Dis 86(4):516\u2013524. https:\/\/doi.org\/10.1053\/j.ajkd.2025.04.020","journal-title":"Am J Kidney Dis"},{"key":"8204_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X251384584","volume":"17","author":"KL McCarty","year":"2025","unstructured":"McCarty KL, Gaffo AL, Diaz-Torne C (2025) Gout therapy updated. Ther Adv Musculoskelet Dis 17:1759720X251384584. https:\/\/doi.org\/10.1177\/1759720X251384584","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"8204_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","volume":"124","author":"RT Keenan","year":"2011","unstructured":"Keenan RT, O\u2019Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS et al (2011) Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 124(2):155\u201363. https:\/\/doi.org\/10.1016\/j.amjmed.2010.09.012","journal-title":"Am J Med"},{"issue":"5","key":"8204_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1001\/jama.2023.26640","volume":"331","author":"N McCormick","year":"2024","unstructured":"McCormick N, Yokose C, Challener GJ, Joshi AD, Tanikella S, Choi HK (2024) Serum urate and recurrent gout. JAMA 331(5):417\u2013424. https:\/\/doi.org\/10.1001\/jama.2023.26640","journal-title":"JAMA"},{"issue":"7","key":"8204_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41584-025-01255-4","volume":"21","author":"HK Ea","year":"2025","unstructured":"Ea HK, Richette P (2025) Factors beyond urate levels for managing gout flares. Nat Rev Rheumatol 21(7):371\u2013372. https:\/\/doi.org\/10.1038\/s41584-025-01255-4","journal-title":"Nat Rev Rheumatol"},{"key":"8204_CR9","doi-asserted-by":"publisher","unstructured":"Xue Y, Chu T, Hu J, Gou W, Zhang N, Li J, Li R, Zhang X, Li Yea et al (2025) Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: a randomized phase 3 trial. Innovation (Camb) 6(8):101015, 101015. https:\/\/doi.org\/10.1016\/j.xinn.2025.101015","DOI":"10.1016\/j.xinn.2025.101015"},{"issue":"1","key":"8204_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12967-025-06072-7","volume":"23","author":"Y Xue","year":"2025","unstructured":"Xue Y, Chu T, Hu J, Gou W, Zhang N, Li J, Li Rea et al (2025) Firsekibart in acute gouty arthritis. J Transl Med 23(1):91. https:\/\/doi.org\/10.1186\/s12967-025-06072-7","journal-title":"J Transl Med"},{"issue":"5","key":"8204_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40744-025-00790-6","volume":"12","author":"N Kong","year":"2025","unstructured":"Kong N, Xue Y, Mao L, Qian L, Guo H, Hu Jea et al (2025) Efficacy and safety of firsekibart compared to etoricoxib for gout flares: a phase 2, multicenter, open-label, active-controlled, randomized non-inferiority trial. Rheumatol Ther 12(5):975\u201390. https:\/\/doi.org\/10.1007\/s40744-025-00790-6","journal-title":"Rheumatol Ther"},{"issue":"11","key":"8204_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70111","volume":"7","author":"Y Yu","year":"2025","unstructured":"Yu Y, Xue Y, Hu J, Zhang N, Li R, Guo H, Yu Jea et al (2025) Firsekibart as a prophylactic treatment for acute gout flare in participants initiating urate-lowering therapy: a phase 2, randomized, open-label, multicenter, active-controlled trial. ACR Open Rheumatol 7(11):e70111. https:\/\/doi.org\/10.1002\/acr2.70111","journal-title":"ACR Open Rheumatol"},{"key":"8204_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152647","volume":"71","author":"J Liu","year":"2025","unstructured":"Liu J, Gamble GD, Dalbeth N (2025) Are participants in gout medication registration clinical trials representative of people with gout in the general population? Semin Arthritis Rheum 71:152647. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152647","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"8204_CR14","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Jansen Tea et al (2015) 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74(10):1789\u201398. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208237","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8204_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40264-022-01265-1","volume":"46","author":"PD Hansten","year":"2023","unstructured":"Hansten PD, Tan MS, Horn JR, Gomez-Lumbreras A, Villa-Zapata L, Boyce Rea et al (2023) Colchicine drug interaction errors and misunderstandings: recommendations for improved evidence-based management. Drug Saf 46(3):223\u201342. https:\/\/doi.org\/10.1007\/s40264-022-01265-1","journal-title":"Drug Saf"},{"issue":"10","key":"8204_CR16","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/acr.22855","volume":"68","author":"A Abhishek","year":"2016","unstructured":"Abhishek A, Valdes AM, Zhang W, Doherty M (2016) Association of Serum Uric Acid and Disease Duration With Frequent Gout Attacks: A Case-Control Study. Arthritis Care Res (Hoboken) 68(10):1573\u20131577. https:\/\/doi.org\/10.1002\/acr.22855","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8204_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-12108-9","author":"Y Wei","year":"2025","unstructured":"Wei Y, Wang K, Liu J, Chen M, Yang Z, Li C, Chen Yea et al (2025) Combination of dual-energy CT findings and clinical features predicts risk of frequent flares of gout. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-025-12108-9","journal-title":"Eur Radiol"},{"issue":"5","key":"8204_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/rhu.0000000000001138","volume":"26","author":"Y Zhuo","year":"2020","unstructured":"Zhuo Y, Cai X, Hou Z, Zhu Z, Cai D (2020) Postoperative Recurrent Gout Flares: A Cross-sectional Study From China. J Clin Rheumatol 26(5):197\u2013203. https:\/\/doi.org\/10.1097\/rhu.0000000000001138","journal-title":"J Clin Rheumatol"},{"issue":"7","key":"8204_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jclinepi.2013.02.002","volume":"66","author":"IF Lin","year":"2013","unstructured":"Lin IF, Chang WP, Liao YN (2013) Shrinkage methods enhanced the accuracy of parameter estimation using Cox models with small number of events. J Clin Epidemiol 66(7):743\u2013751. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.02.002","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"8204_CR20","doi-asserted-by":"publisher","first-page":"795","DOI":"10.18553\/jmcp.2025.31.8.795","volume":"31","author":"JG Rizk","year":"2025","unstructured":"Rizk JG, Qato DM, Bingham CO, dosReis S (2025) Group-based trajectory modeling to assess adherence to chronic urate-lowering therapies among commercially insured US adults with gout. J Manag Care Spec Pharm 31(8):795\u2013807. https:\/\/doi.org\/10.18553\/jmcp.2025.31.8.795","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"8204_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles Aea et al (2020) 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheum 72(6):879\u201395. https:\/\/doi.org\/10.1002\/art.41247","journal-title":"Arthritis Rheum"},{"issue":"1","key":"8204_CR22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13075-023-03098-4","volume":"25","author":"N Schlesinger","year":"2023","unstructured":"Schlesinger N, Pillinger MH, Simon LS, Lipsky PE (2023) Interleukin-1\u03b2 inhibitors for the management of acute gout flares: a systematic literature review. Arthritis Res Ther 25(1):128. https:\/\/doi.org\/10.1186\/s13075-023-03098-4","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"8204_CR23","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","volume":"71","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona Aea et al (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71(11):1839\u201348. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200908","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"8204_CR24","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3899\/jrheum.131226","volume":"41","author":"JS Sundy","year":"2014","unstructured":"Sundy JS, Schumacher HR, Kivitz A, Weinstein SP, Wu R, King-Davis Sea et al (2014) Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol 41(8):1703\u201311. https:\/\/doi.org\/10.3899\/jrheum.131226","journal-title":"J Rheumatol"},{"key":"8204_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key402","author":"CA Janssen","year":"2019","unstructured":"Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen T, Janssen M, Kok MR, Jansen Tea et al (2019) Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/key402","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"8204_CR26","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/art.41699","volume":"73","author":"KG Saag","year":"2021","unstructured":"Saag KG, Khanna PP, Keenan RT, Ohlman S, Osterling Koskinen L, Sparve Eea et al (2021) A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares. Arthritis Rheumatol 73(8):1533\u201342. https:\/\/doi.org\/10.1002\/art.41699","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"8204_CR27","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","volume":"18","author":"JX Li","year":"2022","unstructured":"Li JX, Cummins CL (2022) Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol 18(9):540\u2013557. https:\/\/doi.org\/10.1038\/s41574-022-00683-6","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"8204_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41423-025-01358-8","volume":"22","author":"C Garlanda","year":"2025","unstructured":"Garlanda C, Di Ceglie I, Jaillon S (2025) IL-1 family cytokines in inflammation and immunity. Cell Mol Immunol 22(11):1345\u201362. https:\/\/doi.org\/10.1038\/s41423-025-01358-8","journal-title":"Cell Mol Immunol"},{"key":"8204_CR29","doi-asserted-by":"publisher","first-page":"595936","DOI":"10.3389\/fimmu.2020.595936","volume":"11","author":"N Bhaskaran","year":"2020","unstructured":"Bhaskaran N, Faddoul F, Paes da Silva A, Jayaraman S, Schneider E, Mamileti P et al (2020) IL-1\u03b2-MyD88-mTOR axis promotes immune-protective IL-17A+Foxp3+ cells during mucosal infection and is dysregulated with aging. Front Immunol 11:595936, 595936. https:\/\/doi.org\/10.3389\/fimmu.2020.595936","journal-title":"Front Immunol"},{"issue":"1","key":"8204_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s13287-024-03915-w","volume":"15","author":"J Yan","year":"2024","unstructured":"Yan J, Zhang P, Liu X, Pan C, Shi G, Ye P, Liu Yea et al (2024) Obesity modulates hematopoietic stem cell fate decision via IL-1\u03b2 induced p38\/MAPK signaling pathway. Stem Cell Res Ther 15(1):336. https:\/\/doi.org\/10.1186\/s13287-024-03915-w","journal-title":"Stem Cell Res Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08204-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08204-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08204-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:27:52Z","timestamp":1783398472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08204-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8204"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08204-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was approved by the Ethics Review Committee of First People\u2019s Hospital of Wenling (Ethics approval number: KY-2026\u20132009-01) and the Ethics Review Committee of all the participating centers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}